Hollis-Eden Files IND for NEUMUNE in the U.S.

Hollis-Eden Pharmaceuticals has filed an investigational new drug application with the FDA to begin Phase I clinical trials in human volunteers with NEUMUNE (HE2100) in the U.S.

A similar Phase I clinical trial for NEUMUNE is currently ongoing in the Netherlands. NEUMUNE is being developed for the treatment of acute radiation syndrome (ARS). ARS is a potentially lethal condition caused by high-dose radiation exposure that might result from a nuclear or radiological terrorist attack or from an accident at a nuclear facility.